Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda expands Blowpress portfolio

Takeda expands Blowpress portfolio

18th June 2009

Takeda has further enhanced its portfolio by launching two new dose strengths of Blowpress Plus.

Now available in Germany are fixed-dose combinations of 32 mg candesartan with either 25 mg and 12.5 mg of hydrochlorothiazide.

The additional measurements are intended to be used for patients with essential hypertension whose blood pressure is not adequately controlled by 32 mg candesartan or hydrochlorothiazide monotherapy.

Further introductions of the new doses are expected in other major European markets and the company has so far been granted marketing approval in Spain, Portugal and Austria.

Chief executive of Takeda Pharmaceuticals Europe Erich Brunn explained the Blowpress group of products is the company’s largest selling franchise across the continent.

“The new doses can provide additional blood pressure reduction to hypertensive patients who need more than monotherapy alone,” he said.

Earlier this month, the firm announced it had reviewed its development strategy for the marketing authorisation applications for the investigational compounds alogliptin and alogliptin/actos (pioglitazone HCl) in Europe.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.